[{"address1": "No. 4 The Forum", "address2": "Second Floor Grenville Street", "city": "Saint Helier", "zip": "JE2 4UF", "country": "Jersey", "phone": "44 15 3475 6700", "website": "https://www.novocure.com", "industry": "Medical Devices", "industryKey": "medical-devices", "industryDisp": "Medical Devices", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.", "fullTimeEmployees": 1453, "companyOfficers": [{"maxAge": 1, "name": "Mr. William F. Doyle", "age": 62, "title": "Executive Chairman", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 1427799, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 1, "boardRisk": 4, "compensationRisk": 4, "shareHolderRightsRisk": 3, "overallRisk": 3, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 28.91, "open": 28.04, "dayLow": 27.16, "dayHigh": 28.56, "regularMarketPreviousClose": 28.91, "regularMarketOpen": 28.04, "regularMarketDayLow": 27.16, "regularMarketDayHigh": 28.56, "beta": 0.705, "forwardPE": -16.867811, "volume": 1241775, "regularMarketVolume": 1241775, "averageVolume": 1378531, "averageVolume10days": 894020, "averageDailyVolume10Day": 894020, "bid": 27.38, "ask": 27.5, "bidSize": 400, "askSize": 400, "marketCap": 2970117632, "fiftyTwoWeekLow": 11.7, "fiftyTwoWeekHigh": 34.13, "priceToSalesTrailing12Months": 5.140942, "fiftyDayAverage": 24.2271, "twoHundredDayAverage": 19.2072, "currency": "USD", "enterpriseValue": 2685857280, "profitMargins": -0.25926, "floatShares": 98520652, "sharesOutstanding": 108201000, "sharesShort": 5192908, "sharesShortPriorMonth": 5669287, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.048, "heldPercentInsiders": 0.09628, "heldPercentInstitutions": 0.87483, "shortRatio": 3.09, "shortPercentOfFloat": 0.0573, "impliedSharesOutstanding": 113956000, "bookValue": 3.337, "priceToBook": 8.225952, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -149784000, "trailingEps": -1.39, "forwardEps": -1.5, "enterpriseToRevenue": 4.649, "enterpriseToEbitda": -19.101, "52WeekChange": 1.1803019, "SandP52WeekChange": 0.22263205, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "NVCR", "underlyingSymbol": "NVCR", "shortName": "NovoCure Limited", "longName": "NovoCure Limited", "firstTradeDateEpochUtc": 1443706200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "bfab5876-779c-323f-b689-a628956af770", "messageBoardId": "finmb_69172456", "gmtOffSetMilliseconds": -18000000, "currentPrice": 27.45, "targetHighPrice": 46.0, "targetLowPrice": 29.0, "targetMeanPrice": 36.71429, "targetMedianPrice": 38.0, "recommendationMean": 1.85714, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 959897984, "totalCashPerShare": 8.871, "ebitda": -140611008, "totalDebt": 675625984, "quickRatio": 1.432, "currentRatio": 1.49, "totalRevenue": 577737984, "debtToEquity": 187.268, "revenuePerShare": 5.375, "returnOnAssets": -0.07927, "returnOnEquity": -0.39705002, "freeCashflow": 823500, "operatingCashflow": -37476000, "revenueGrowth": 0.218, "grossMargins": 0.76551, "ebitdaMargins": -0.24338, "operatingMargins": -0.20692, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-11"}]